On Friday, Mineralys Therapeutics Inc (NASDAQ: MLYS) opened lower -3.43% from the last session, before settling in for the closing price of $14.15. Price fluctuations for MLYS have ranged from $8.24 to $18.38 over the past 52 weeks.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
During the last 5-year period, the sales drop of Healthcare Sector giant was -170.42%. Company’s average yearly earnings per share was noted 15.68% at the time writing. With a float of $40.63 million, this company’s outstanding shares have now reached $64.88 million.
Let’s determine the extent of company efficiency that accounts for 51 employees. In terms of profitability, gross margin is 0.0%, operating margin of 0.0%, and the pretax margin is 0.0%.
Mineralys Therapeutics Inc (MLYS) Breakdown of a Key Holders of the stock
A key investor’s attitude towards the stock of the Biotechnology industry is another important factor to consider. The insider ownership of Mineralys Therapeutics Inc is 37.65%, while institutional ownership is 64.91%. The most recent insider transaction that took place on Jul 30 ’25, was worth 884,372. In this transaction CFO and Secretary of this company sold 59,925 shares at a rate of $14.76, taking the stock ownership to the 132,934 shares. Before that another transaction happened on Jul 28 ’25, when Company’s CFO and Secretary sold 12,946 for $14.04, making the entire transaction worth $181,803. This insider now owns 193,666 shares in total.
Mineralys Therapeutics Inc (MLYS) Recent Fiscal highlights
Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.73 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 15.68% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 2.14% during the next five years compared to -170.42% drop over the previous five years of trading.
Mineralys Therapeutics Inc (NASDAQ: MLYS) Trading Performance Indicators
Check out the current performance indicators for Mineralys Therapeutics Inc (MLYS). In the past quarter, the stock posted a quick ratio of 26.48.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -3.74, a number that is poised to hit -0.74 in the next quarter and is forecasted to reach -3.13 in one year’s time.
Technical Analysis of Mineralys Therapeutics Inc (MLYS)
Looking closely at Mineralys Therapeutics Inc (NASDAQ: MLYS), its last 5-days average volume was 0.72 million, which is a drop from its year-to-date volume of 0.88 million. As of the previous 9 days, the stock’s Stochastic %D was 48.10%.
During the past 100 days, Mineralys Therapeutics Inc’s (MLYS) raw stochastic average was set at 40.62%, which indicates a significant increase from 25.36% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 0.73 in the past 14 days, which was lower than the 0.99 volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $14.61, while its 200-day Moving Average is $13.15. However, in the short run, Mineralys Therapeutics Inc’s stock first resistance to watch stands at $14.20. Second resistance stands at $14.74. The third major resistance level sits at $15.01. If the price goes on to break the first support level at $13.39, it is likely to go to the next support level at $13.11. Now, if the price goes above the second support level, the third support stands at $12.58.
Mineralys Therapeutics Inc (NASDAQ: MLYS) Key Stats
There are currently 65,175K shares outstanding in the company with a market cap of 890.62 million. Presently, the company’s annual sales total 0 K according to its annual income of -177,810 K. Last quarter, the company’s sales amounted to 0 K and its income totaled -42,210 K.
